Amedisys (AMED)
(Delayed Data from NSDQ)
$99.31 USD
+0.81 (0.82%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $99.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Amedisys, Inc. has a PEG ratio of 1.40 compared to the Medical - Outpatient and Home Healthcare industry's PEG ratio of 1.60.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMED 99.31 +0.81(0.82%)
Will AMED be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMED
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
Can BrightSpring's Q1 Strength Carry Through 2025 Headwinds?
Other News for AMED
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
Decoding Amedisys Inc (AMED): A Strategic SWOT Insight
Amedisys (AMED) Exceeds Q2 Revenue Expectations
Amedisys Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $621. ...
Amedisys Inc (AMED) Reports Q2 2025 Financial Results | AMED stock news